TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23234880
Drug: EHT 0202
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHT 0202 (40 and 80 mg bid)
Study: 22059476
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (LdAA) preoperatively (≤320 mg daily)
Study: 22059476
Drug: No low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No low-dose acetylsalicylic acid (LdAA) preoperatively
Study: 22059476
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (LdAA) preoperatively
Study: 14721997
Drug: Biventricular pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular pacing (resynchronization therapy)
Study: 9765759
Drug: Postoperative cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin-based chemotherapy alone
Study: 9765759
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with radiotherapy
Study: 9765759
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with alkylating agents
Study: 9765759
Drug: Prolonged adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged adjuvant chemotherapy (busulfan or cytoxan daily for 2 years)
Study: 9765759
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide doxorubicin-cisplatin (CAP)
Study: 9765759
Drug: Current chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current chemotherapy regimens
Study: 3320136
Drug: Family-patient teaching
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-patient teaching programme (twice a week)
Study: 27493100
Drug: Probucol 250
Normalized name: probucol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 250 mg/d
Study: 27493100
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg/d
Study: 25795699
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF; lenograstim) 15 µg/kg body weight daily on days 1-5
Study: 25795699
Drug: G-CSF 15
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 15 µg/kg body weight daily on days 1-5 followed by leukapheresis, isolation and aliquoting of CD133+ cells, infusion of freshly isolated CD133+ cells immediately and frozen doses at days 30 and 60 (0.2×10(6) cells/kg for each of the three doses)
Study: 23912172
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic antibodies)
Study: 11064850
Drug: Exercise alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise alone, details on dosage and duration not specified
Study: 8630721
Drug: Extended-release albuterol
Normalized name: albuterol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release albuterol tablets (4 mg twice daily, increasing up to 12 mg q 12h)
Study: 8161670
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg q.d.s.)
Study: 3948141
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (Roferon‐A), 36 X 10(6)U intramuscularly 3 times weekly
Study: 3948141
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (Roferon‐A) in combination with vinblastine, 0.10‐0.15 mg/kg intravenously every 2 to 3 weeks
Study: 26275686
Drug: Cyclosporine-A 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine-A 0.05% ophthalmic emulsion
Study: 22488662
Drug: Cohorts 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1 + 2 (n = 68) with standard induction therapy
Study: 22488662
Drug: Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3 (n = 141) with modified induction therapy (prednisone 40 mg/m(2)/day, short infusion daunorubicin 30 minutes)
Study: 20007756
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (CS) 135 mg three times daily for 8 weeks
Study: 12605350
Drug: Agnus castus
Normalized name: Vitex agnus-castus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agnus castus (AC: 120 ‐ 480 mg/die) for 14 days
Study: 6151504
Drug: Propranolol (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1-8 mg)
Study: 6151504
Drug: Pindolol (0.1-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.1-0.8 mg)
Study: 6151504
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. Propranolol (8 mg)
Study: 6151504
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. Pindolol (0.8 mg)
Study: 20190601
Drug: Landiolol (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (treatment L)
Study: 20190601
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment C)
Study: 11827919
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (warfarin plus aspirin)
Study: 10406248
Drug: Flumazenil (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.01 mg/kg, maximum 1.0 mg)
Study: 12118494
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous normal saline)
Study: 7555258
Drug: oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral low-dose acyclovir (600-800 mg per day)
Study: 1701507
Drug: topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical corticosteroids in combination with antibiotics
Study: 31631361
Drug: Three fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three fractional ablative CO2 laser treatments at 8‐week intervals
Study: 25009161
Drug: Olanzapine (OLZ)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLZ) 2.5‐20 mg/d
Study: 25009161
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic (CNV)
Study: 23720078
Drug: Tramadol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (2 mg.kg-1)
Study: 23720078
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg.kg-1)
Study: 21630032
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (1 g twice daily)
Study: 19646281
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (full mouth non-surgical scaling and root planing, systemic antibiotherapy, local antiseptics (chlorhexidine 0.12%), and oral health instructions)
Study: 15153205
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Study: 15153205
Drug: Remifentanil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Study: 9572229
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 microg every 4 hours for three doses with or without oxytocin)
Study: 9572229
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline infusion and oxytocin
Study: 2568016
Drug: Omeprazole (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (specific dosage and duration not available)
Study: 2568016
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (specific details not available)
Study: 2568016
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (specific details not available)
Study: 2568016
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs (specific details not available)
Study: 31101700
Drug: Dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg three times a day
Study: 31101700
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide inhaler 20 μg two puffs three times a day
Study: 31101700
Drug: Honey 30
Normalized name: SIMPLYTHICK ORAL GEL HONEY 30GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey 30 mg (a spoonful) three times a day
Study: 28605109
Drug: Valnoctamide 1500
Normalized name: valnoctamide
DrugBank: Valnoctamide (DB13099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valnoctamide 1500 mg/d (n=71)
Study: 28605109
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/d (n=32)
Study: 25470423
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT)
Study: 21136213
Drug: Navcap (V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navcap (V 25 mg/m2 on d1 and d8 and C 825 mg/m2 bid D1‐14 q3w) for 4 cycles followed by Navcap (A)
Study: 21136213
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (25 mg/m²/week) for 12 cycles (B)
Study: 17519305
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d for 3 months
Study: 15122531
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three specimens (first-void urine, urethral swabs, semen)
Study: 9566830
Drug: Silymarin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (450 mg, 150 mg three times per day)
Study: 8169656
Drug: Sustained‐release ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained‐release ferrous sulfate (150 mg) daily for 14 weeks
Study: 8169656
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets daily for 14 weeks
Study: 3414573
Drug: Balloon filled
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon filled with 400 mL water
Study: 3414573
Drug: Balloon filled
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon filled with 600 mL water
Study: 3414573
Drug: Balloon filled
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon filled with 800 mL water
Study: 3414573
Drug: Balloon filled
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon filled with 0 mL water
Study: 3414573
Drug: Balloon filled
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon filled with 200 mL water
Study: 27029284
Drug: One-pill DAPT
Normalized name: Vitafol-One Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-pill DAPT
Study: 27029284
Drug: Two-pill DAPT
Normalized name: Two-Dyne Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-pill DAPT
Study: 24967362
Drug: Patients positive
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients positive to antinuclear antibodies
Study: 24967362
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug users
Study: 24967362
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration route
Study: 22643944
Drug: Antibiotics (cefazolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefazolin at 1.0 g i.v.) only at anesthetic induction
Study: 22643944
Drug: Antibiotics (cefazolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefazolin at 1.0 g i.v. at anesthetic induction and oral amoxicillin at 1 g every 12 hours for 7 days)
Study: 18482233
Drug: Intravenous propacetamol
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propacetamol (40 mg.kg(‐1) via 15 min infusion)
Study: 18482233
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (20 mg.kg(‐1) every 6 h)
Study: 11996473
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF regimen (cyclophosphamide 100 mg/m2 p.o. on days 1 to 14, methotrexate 40 mg/m2 i.v. on days 1 and 8, 5‐fluorouracil 600 mg/ml i.v. on days 1 and 8; cycles q. 28 days)
Study: 10862204
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy with patch closure (CEAP)
Study: 28686776
Drug: A/BPO gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/BPO gel 0.3%/2.5%
Study: 26000685
Drug: Subfascial ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial ultrasound-guided stellate ganglion block with 4 mL of 0.375% levobupivacaine (group S)
Study: 23597267
Drug: Strawberry-flavoured placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry-flavoured placebo preparations
Study: 21266447
Drug: Dietary plant-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary plant-derived polysaccharide supplement (AC)
Study: 17174508
Drug: Clarithromycin tablet
Normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablet formulation 1
Study: 17174508
Drug: Clarithromycin tablet
Normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablet formulation 2
Study: 15098801
Drug: Ondansetron solution
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron solution (4 mg)
Study: 15098801
Drug: Extemporaneous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extemporaneous ondansetron capsule formulation (4 mg)
Study: 11408420
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Study: 2493523
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin ointment (NTG)
Study: 28455182
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (2 doses of 20 mg/kg)
Study: 28455182
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3.0 g)
Study: 28455182
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (2 doses of 20 mg/kg)
Study: 27208386
Drug: DIMS0150 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIMS0150 (30 mg)
Study: 17532963
Drug: MC-1 250
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1 250 mg
Study: 15478487
Drug: Self-etching agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching agents (Prompt‐L Pop, Adper Prompt, Clearfil SE, Prime& Bond NT with NRC, Xeno111, One‐Up Bond, AdheSe)
Study: 9627258
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (4 mg/kg of 2% lidocaine applied to subglottic, glottic, and supraglottic areas before intubation)
Study: 9627258
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1 mg/kg of 2% lidocaine before extubation)
Study: 9627258
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (used topically in the first control group)
Study: 3276150
Drug: Oral miconazole
Normalized name: miconazole Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral miconazole
Study: 29733445
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 70 μg/d
Study: 26304595
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type I receptor blocker (ARB) medication
Study: 26304595
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of eUUN or protein intake during ARB treatment
Study: 23098134
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all hypertension medications upon awakening
Study: 23098134
Drug: Ingesting ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting ≥1 hypertension medications at bedtime
Study: 23098134
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all hypertension medications at bedtime
Study: 18315706
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous furosemide
Study: 18315706
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous furosemide infusion
Study: 12690278
Drug: Amoxicillin/clavulanate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (25 mg/kg every 12 h)
Study: 7685428
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg daily for 24 weeks
Study: 2404631
Drug: Colestipol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol plus niacin therapy
Study: 7000168
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg thrice daily)
Study: 28697785
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy program (12 weeks, aerobic and functional exercises in circuit training)
Study: 15483801
Drug: Lateral joint
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral joint line injection
Study: 15483801
Drug: Superomedial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superomedial injection
Study: 15483801
Drug: Superolateral injection
Normalized name: TITANIUM DIOXIDE 4 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL CREAM [supernatural poreless tint spf 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superolateral injection
Study: 9044517
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of papaverine
Study: 8172713
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg once daily
Study: 8172713
Drug: Casodex 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 100 mg/day
Study: 30087040
Drug: CDM Group-II
Normalized name: Corticosteroids, moderately potent (group II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDM Group-II (additional interventions including early postpartum follow-up and beta-blocker therapy)
Study: 23106760
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling with positive alliance with counselor
Study: 23106760
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling with advice from counselor and group members
Study: 23106760
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling with self-disclosure and participation
Study: 20579938
Drug: Desmopressin (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.2-0.4 mg daily)
Study: 29995359
Drug: Escitalopram 5-10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 5-10 mg/d
Study: 27084692
Drug: Escitalopram 10-20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg/d
Study: 17012890
Drug: DTPw-HepB-Hib combination
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HepB-Hib combination vaccine (Quinvaxem)
Study: 17012890
Drug: DTPw-Hib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-Hib and hepatitis B vaccines (comparator group)
Study: 14609821
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord serum therapy
Study: 27921414
Drug: Autologous serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous serum therapy
Study: 9220839
Drug: Unna's boot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unna's boot and activated charcoal treatment
Study: 26667403
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (10 mg)
Study: 24218006
Drug: Basel cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basel cocktail (low doses of caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam)
Study: 18310583
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CCBT)
Study: 18310583
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CCBT) followed by mirtazapine